Home › Type 1 Diabetes
Type 1 Diabetes clinical trials recruiting in the U.S.
138 studies for Type 1 Diabetes are recruiting participants at sites across the United States.
If the pancreas doesn't make needed insulin, causing blood sugar levels to be too high you have type 1 or juvenile diabetes. Learn the signs.
Cities with the most studies
- Aurora, CO23 studies
- Boston, MA21 studies
- Seattle, WA18 studies
- Chicago, IL16 studies
- New Haven, CT15 studies
- New York City, NY15 studies
- San Francisco, CA14 studies
- Miami, FL13 studies
- Indianapolis, IN13 studies
- Gainesville, FL12 studies
- Atlanta, GA11 studies
- Philadelphia, PA11 studies
- Durham, NC10 studies
- Minneapolis, MN10 studies
- Houston, TX9 studies
- Charlottesville, VA9 studies
- Nashville, TN8 studies
- Dallas, TX7 studies
- Cleveland, OH7 studies
- Orlando, FL7 studies
- Pittsburgh, PA7 studies
- Baltimore, MD6 studies
- San Diego, CA6 studies
- Buffalo, NY6 studies
- Kansas City, MO6 studies
- Los Angeles, CA6 studies
- Columbus, OH6 studies
- Tampa, FL5 studies
- Jacksonville, FL5 studies
- Detroit, MI5 studies
- Rochester, MN4 studies
- Memphis, TN4 studies
- Mountain View, CA4 studies
- Baldwin Park, CA4 studies
- Louisville, KY4 studies
- Austin, TX3 studies
- Ann Arbor, MI3 studies
- St. Louis, MO3 studies
- Concord, CA3 studies
- Portland, OR3 studies
By state
- Arizona3 studies
- California37 studies
- Colorado24 studies
- Connecticut16 studies
- Florida30 studies
- Georgia13 studies
- Illinois16 studies
- Indiana13 studies
- Kentucky6 studies
- Maryland6 studies
- Massachusetts21 studies
- Michigan8 studies
- Minnesota13 studies
- Missouri9 studies
- New York23 studies
- North Carolina12 studies
- Ohio13 studies
- Oregon3 studies
- Pennsylvania13 studies
- Tennessee11 studies
- Texas16 studies
- Utah5 studies
- Virginia10 studies
- Washington20 studies
- Wisconsin3 studies
Recently updated studies
Starting Technology in At Risk Type 1 Diabetes Study
Recruiting
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06453928ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
Recruiting
Ages 8 to 21 · All sexes · Updated Sep 23, 2026 · NCT05463289A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 23, 2026 · NCT07803744App-Based Certified Diabetes Education Therapy (AB-CDE)
Recruiting
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07282639A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
RecruitingPhase 3
Ages 1 to 35 · All sexes · Updated Sep 22, 2026 · NCT07222332A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
RecruitingPhase 3
Ages 1 to 35 · All sexes · Updated Sep 22, 2026 · NCT07222137Type 1 Diabetes Extension Study
RecruitingObservational study
Ages 8 to 35 · All sexes · Updated Sep 18, 2026 · NCT02734277METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
RecruitingPhase 2
Ages 18 to 69 · All sexes · Updated Sep 15, 2026 · NCT07699380A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 14, 2026 · NCT07088068CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RecruitingPhase 1/2
Ages 12 to 35 · All sexes · Updated Sep 11, 2026 · NCT06783309Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
RecruitingPhase 2
Ages 4 to 34 · All sexes · Updated Sep 9, 2026 · NCT07216391Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes
Recruiting
Ages 16 to 50 · All sexes · Updated Sep 8, 2026 · NCT05540704Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
RecruitingPhase 2
Ages 8 to 45 · All sexes · Updated Sep 8, 2026 · NCT07142252C-Carbs: A CGM-guided Approach to Teaching Carb Awareness
Recruiting
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07807280The iLet Experience Study
RecruitingObservational study
Ages 6 and older · All sexes · Updated Sep 8, 2026 · NCT06891898A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
RecruitingPhase 1/2
Ages 9 to 20 · All sexes · Updated Sep 2, 2026 · NCT07061574A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 1, 2026 · NCT04786262Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
Recruiting
Ages 8 to 65 · All sexes · Updated Sep 1, 2026 · NCT05268250Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
Recruiting
Ages 18 to 80 · All sexes · Updated Aug 28, 2026 · NCT07599982HLA Demographics Study in Adults With Type 1 Diabetes
RecruitingObservational study
Ages 18 to 55 · All sexes · Updated Aug 28, 2026 · NCT06860516Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring
RecruitingHealthy volunteers welcome
Ages 18 to 90 · All sexes · Updated Aug 28, 2026 · NCT07254364Pilot Implementation Trial of Implementation Toolkits for Diabetes Coaching
RecruitingHealthy volunteers welcome
All ages · All sexes · Updated Aug 27, 2026 · NCT07766811Family Intervention for Black Teens With Type 1 Diabetes
Recruiting
Ages 10 to 14 · All sexes · Updated Aug 27, 2026 · NCT06275412Long-Term Outcomes of Teplizumab in Routine Clinical Care
RecruitingObservational study
All ages · All sexes · Updated Aug 25, 2026 · NCT07360080SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
RecruitingPhase 2
Ages 5 to 40 · All sexes · Updated Aug 24, 2026 · NCT07187531From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.